ME01537B - Spojevi spiropiperidona kao antagonisti receptora orl-1 - Google Patents
Spojevi spiropiperidona kao antagonisti receptora orl-1Info
- Publication number
- ME01537B ME01537B MEP-2013-118A MEP11813A ME01537B ME 01537 B ME01537 B ME 01537B ME P11813 A MEP11813 A ME P11813A ME 01537 B ME01537 B ME 01537B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- methyl
- compound according
- ylmethyl
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title description 3
- 229940044551 receptor antagonist Drugs 0.000 title description 3
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 title description 2
- 108010020615 nociceptin receptor Proteins 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 14
- -1 cyano, cyanomethyl Chemical group 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 13
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 229910052801 chlorine Chemical group 0.000 claims 3
- 239000000460 chlorine Chemical group 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- NKQHBJNRBKHUQR-UHFFFAOYSA-N [2-[4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methylpyrazol-1-yl]pyridin-3-yl]methanol Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=NC=CC=C1CO NKQHBJNRBKHUQR-UHFFFAOYSA-N 0.000 claims 2
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 claims 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims 1
- XTVMMUUMUBGOPK-UHFFFAOYSA-N 2-chloro-4,4-difluoro-1'-[[3-methyl-1-[3-(pyrazol-1-ylmethyl)pyridin-2-yl]pyrazol-4-yl]methyl]spiro[5h-thieno[2,3-c]pyran-7,4'-piperidine] Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(C)=NN1C1=NC=CC=C1CN1C=CC=N1 XTVMMUUMUBGOPK-UHFFFAOYSA-N 0.000 claims 1
- TVSCFMXJYNZEER-UHFFFAOYSA-N 7-methoxy-11a-methyl-1,9b,10,11-tetrahydronaphtho[1,2-g]indole Chemical compound C1CC2(C)CC=NC2=C2C=CC3=CC(OC)=CC=C3C21 TVSCFMXJYNZEER-UHFFFAOYSA-N 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- ZAOZBWZTMUTPSX-UHFFFAOYSA-N [4-[(2-chloro-4,4-difluorospiro[5h-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-1-(3-fluoropyridin-2-yl)pyrazol-3-yl]methanol Chemical compound C1=C(CN2CCC3(CC2)C=2SC(Cl)=CC=2C(F)(F)CO3)C(CO)=NN1C1=NC=CC=C1F ZAOZBWZTMUTPSX-UHFFFAOYSA-N 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004859 cyclopropyloxymethyl group Chemical group C1(CC1)OC* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 241000884009 Hyporhamphus unifasciatus Species 0.000 description 1
- 241001417524 Pomacanthidae Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
"(12) PATENTNI SPIS<br /> 1 <br />me<br />B 01537 ME<br />(11)<br />ME 01537B (19) Crna Gora<br />(21) Broj prijave: P-2013-118<br />(22) Datum podnošenja prijave: 10. 11. 2010<br />(43) Datum objavljivanja prijave:<br />(45) Datum objavljivanja patenta:<br />2040420<br />20. 04. 2014<br /> Glasnik : 14/2014<br /> (51) Me dunarodna klasifikacija MKP<br />C07D495/20<br />2006.01<br />A61K31/444<br />2006.01<br />A61P25/00<br />2006.01<br />(30) Me dunarodno pravo prvenstva<br />EP<br />20090382246<br />16. 11. 2009<br />US<br />20100298629P<br />27. 01. 2010<br />(73) Nosilac Patenta<br />Eli Lilly and Company<br />Lilly Corporate Center<br />Indianapolis, IN 46285<br />US<br />(74) Zastupnik:<br />attorney<br />CUPI C, Branislav<br />Dalmatinska 10<br />Podgorica<br />81000<br />ME<br /> (72) Pronalaza c<br />BENITO COLLADO, Ana Belen<br />Lilly S.A., Avendia de la Industria 30<br />28108 Alcobendas Madrid<br />ES<br />DIAZ BUEZO, Nuria<br />Lilly S.A., Avendia de la Industria 30<br />Madrid<br />ES<br />JIMENEZ-AGUADO, Alma Maria<br />Lilly S.A., Avendia de la Industria 30<br />Madrid<br />ES<br />LAFUENTE BLANCO, Celia<br />Lilly S.A., Avendia de la Industria 30<br />Madrid<br />ES<br />MARTINEZ-GRAU, Maria Angeles<br />Lilly S.A., Avendia de la Industria 30<br />Madrid<br />ES<br />PEDREGAL-TERCERO, Concepcion<br />Lilly S.A., Avendia de la Industria 30<br />Madrid<br />ES<br />TOLEDO ESCRIBANO, Miguel Angel<br />Lilly S.A., Avendia de la Industria 30<br />Madrid<br />ES<br />(54) Naziv:<br />me<br />SPOJEVI SPIROPIPERIDONA KAO ANTAGONISTI RECEPTORA ORL-l<br />en<br />SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS<br />(57) Apstrakt:"
Claims (15)
1.Spoj formule:,naznačen time štoR1 je fluor ili klor;svaki od R2a i R2b je vodik ili fluor;R3 je vodik, metil, hidroksimetil ili (C1-C3) alkoksimetil;R4 se bira iz skupine koju čine fluor, klor, cijano, cijanometil, (C1-C3) alkil, ciklopropil, hidroksimetil, metoksi, ciklopropilmetoksi, aminokarbonilmetoksi, (C1-C3) alkoksimetil, ciklopropiloksimetil, ciklopropilmetoksimetil, 1-hidroksi-1-metiletil, aminokarboniloksimetil, metilaminokarboniloksimetil, dimetilaminokarboniloksimetil, aminokarbonil, aminokarbonilmetil, -CH2-NR5R6, hidroksiimin, metoksiimin, morfolin-4-il, morfolin-4-ilmetil, Ar1, -CH2Ar1, tetrahidrofuran-2-il, 3-oksomorfolin-4-ilmetil, 2-oksopirolidin-1-ilmetil i 2-oksopiperidin-1-ilmetil;R5 je vodik, C1-C3 alkil, cijanometil, -C(O)CH3, ili aminokarbonilmetil;R6 je vodik ili metil; iAr1 je ostatak kojeg se bira iz skupine koju čine imidizol-1-il, imidizol-2-il, 2-metilimidizol-1-il, pirazol-1-il, 1,2,3-triazol-1-il; 1,2,3-triazol-2-il; 1,2,4-triazol-1-il, isoksazol-3-il, oksazol-5-il, i 3-metil-1,2,4-oksadiazol-5-il; ilinjegova farmaceutski prihvatljiva sol.
2.Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je klor, ili njegova farmaceutski prihvatljiva sol.
3.Spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što svaki od R2a i R2b je fluor, ili njegova farmaceutski prihvatljiva sol.
4.Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je fluor, a svaki od R2a i R2b je vodik, ili njegova farmaceutski prihvatljiva sol.
5.Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što R3 je metil, ili njegova farmaceutski prihvatljiva sol.
6.Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što R4 je fluor, hidroksimetil, metoksimetil ili pirazol-1-ilmetil, ili njegova farmaceutski prihvatljiva sol.
7.Spoj u skladu s patentnim zahtjevom 1, naznačen time što je [2-[4-[(2-klor-4,4-difluorspiro[5H-tieno[2,3-c]piran-7,4′-piperidin]-1′-il)metil]-3-metilpirazol-1-il]-3-piridil]metanol; 2-klor-4,4-difluor-1′-[[3-metil-1-[3-(pirazol-1-ilmetil)-2-piridil]pirazol-4-il]metil]spiro[5H-tieno[2,3-c]piran-7,4′-piperidin]; ili [4-[(2-klor-4,4-difluorspiro[5H-tieno[2,3-c]piran-7,4′-piperidin]-1′-il)metil]-1-(3-fluor-2-piridil)pirazol-3-il]metanol; ili njihove farmaceutski prihvatljive soli.
8.Spoj u skladu s patentnim zahtjevom 1, naznačen time što je [2-[4-[(2-klor-4,4-difluorspiro[5H-tieno[2,3-c]piran-7,4′-piperidin]-1′-il)metil]-3-metilpirazol-1-il]-3-piridil]metanol, ili njegova farmaceutski prihvatljiva sol.
9.Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
10.Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što dodatno sadrži najmanje jedan dodatni terapijski sastojak.
11.Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što je dodatni terapijski sastojak SSRI antidepresiv.
12.Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen za uporabu u terapiji.
13.Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 12, u liječenju pretilosti ili prekomjerne tjelesne težine kod čovjeka.
14.Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 12, u liječenju migrene.
15.Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 12, u liječenju depresije.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382246 | 2009-11-16 | ||
| US29862910P | 2010-01-27 | 2010-01-27 | |
| EP10782482.3A EP2501703B1 (en) | 2009-11-16 | 2010-11-10 | Spiropiperidine compounds as orl-1 receptor antagonists |
| PCT/US2010/056180 WO2011060035A1 (en) | 2009-11-16 | 2010-11-10 | Spiropiperidine compounds as orl-1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01537B true ME01537B (me) | 2014-04-20 |
Family
ID=41728051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2013-118A ME01537B (me) | 2009-11-16 | 2010-11-10 | Spojevi spiropiperidona kao antagonisti receptora orl-1 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8232289B2 (me) |
| EP (1) | EP2501703B1 (me) |
| JP (1) | JP5680101B2 (me) |
| KR (1) | KR101363830B1 (me) |
| CN (1) | CN102612520B (me) |
| AR (1) | AR078863A1 (me) |
| AU (1) | AU2010319581C1 (me) |
| CA (1) | CA2796161C (me) |
| CO (1) | CO6541545A2 (me) |
| CR (1) | CR20130087A (me) |
| DK (1) | DK2501703T3 (me) |
| DO (1) | DOP2012000135A (me) |
| EA (1) | EA020848B1 (me) |
| EC (1) | ECSP12011902A (me) |
| ES (1) | ES2435814T3 (me) |
| HN (1) | HN2012001011A (me) |
| HR (1) | HRP20130967T1 (me) |
| IL (1) | IL219370A (me) |
| JO (1) | JO2887B1 (me) |
| MA (1) | MA33751B1 (me) |
| ME (1) | ME01537B (me) |
| MX (1) | MX2012005691A (me) |
| MY (1) | MY160665A (me) |
| NZ (1) | NZ600006A (me) |
| PE (1) | PE20121430A1 (me) |
| PH (1) | PH12012500969A1 (me) |
| PL (1) | PL2501703T3 (me) |
| PT (1) | PT2501703E (me) |
| RS (1) | RS53018B (me) |
| SI (1) | SI2501703T1 (me) |
| TW (1) | TWI465453B (me) |
| UA (1) | UA107943C2 (me) |
| WO (1) | WO2011060035A1 (me) |
| ZA (1) | ZA201202967B (me) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2781716A1 (en) | 2009-12-04 | 2011-06-09 | Sunovion Pharmaceuticals Inc. | Multicyclic thieno compounds and use thereof for the treatment of a neurological disorder |
| US9394290B2 (en) * | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| TWI582096B (zh) * | 2011-12-06 | 2017-05-11 | 美國禮來大藥廠 | 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物 |
| TW201416370A (zh) | 2012-07-31 | 2014-05-01 | Lilly Co Eli | 用於治療焦慮之ｏｒｌ－１受體拮抗劑 |
| RU2641916C2 (ru) | 2012-10-02 | 2018-01-23 | Байер Кропсайенс Аг | Гетероциклические соединения в качестве пестицидов |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
| JO3638B1 (ar) * | 2015-09-09 | 2020-08-27 | Lilly Co Eli | مركبات مفيدة في تثبيط ror - جاما- t |
| AU2017301769B2 (en) | 2016-07-29 | 2022-07-28 | Pgi Drug Discovery Llc | Compounds and compositions and uses thereof |
| SG10202100751YA (en) | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| AU2018220509B2 (en) | 2017-02-16 | 2022-04-28 | Sumitomo Pharma America, Inc. | Methods of treating schizophrenia |
| EP3589637B1 (en) * | 2017-03-02 | 2021-04-14 | Eli Lilly and Company | Compounds useful for inhibiting ror-gamma-t |
| HRP20210898T1 (hr) | 2017-03-02 | 2021-08-20 | Eli Lilly And Company | SPOJEVI KORISNI ZA INHIBIRANJE ROR-γ-T |
| SG11202000669VA (en) | 2017-08-02 | 2020-02-27 | Sunovion Pharmaceuticals Inc | Isochroman compounds and uses thereof |
| CA3091292A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
| CN113453760B (zh) | 2018-12-17 | 2024-05-24 | 弗特克斯药品有限公司 | Apol1抑制剂及其使用方法 |
| JP7703449B2 (ja) | 2019-03-14 | 2025-07-07 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 |
| CN115734785A (zh) | 2020-04-14 | 2023-03-03 | 桑诺维恩药品公司 | (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症 |
| CA3183591A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and using the same |
| IL300298B2 (en) | 2020-08-26 | 2025-06-01 | Vertex Pharma | Inhibitors of apol1 and methods of using same |
| JP2025505647A (ja) * | 2022-02-08 | 2025-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｐｏｌ１阻害剤としての２－メチル－４’，５’－ジヒドロピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、およびそれを使用する方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| DE60033071T2 (de) * | 1999-12-06 | 2007-08-23 | Euro-Celtique S.A. | Triazospiroverbindungen mit nociceptin-rezeptoraffinität |
| IL158485A0 (en) * | 2001-04-18 | 2004-05-12 | Euro Celtique Sa | Spiropyrazole compounds |
| WO2002088089A1 (en) | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions |
| JP4356453B2 (ja) * | 2001-07-23 | 2009-11-04 | 萬有製薬株式会社 | ４−オキソイミダゾリジン−２−スピロピペリジン誘導体 |
| JP2005519921A (ja) * | 2002-01-28 | 2005-07-07 | ファイザー株式会社 | Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物 |
| WO2003095427A1 (en) | 2002-05-10 | 2003-11-20 | Taisho Pharmaceutical Co.,Ltd. | Spiro-ring compound |
| US6995168B2 (en) * | 2002-05-31 | 2006-02-07 | Euro-Celtique S.A. | Triazaspiro compounds useful for treating or preventing pain |
| US7081463B2 (en) * | 2002-09-09 | 2006-07-25 | Janssen Pharmaceutica N.V. | Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders |
| WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| WO2005092858A2 (en) * | 2004-03-29 | 2005-10-06 | Pfizer Japan Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist |
| DE102004039382A1 (de) * | 2004-08-13 | 2006-02-23 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| PL2260042T3 (pl) * | 2008-03-27 | 2012-02-29 | Gruenenthal Gmbh | Podstawione spirocykliczne pochodne cykloheksanu |
-
2010
- 2010-10-11 UA UAA201205367A patent/UA107943C2/uk unknown
- 2010-11-02 AR ARP100104035A patent/AR078863A1/es active IP Right Grant
- 2010-11-03 JO JO2010386A patent/JO2887B1/en active
- 2010-11-05 TW TW099138241A patent/TWI465453B/zh not_active IP Right Cessation
- 2010-11-10 PL PL10782482T patent/PL2501703T3/pl unknown
- 2010-11-10 KR KR1020127012498A patent/KR101363830B1/ko not_active Expired - Fee Related
- 2010-11-10 AU AU2010319581A patent/AU2010319581C1/en not_active Ceased
- 2010-11-10 PT PT107824823T patent/PT2501703E/pt unknown
- 2010-11-10 CA CA2796161A patent/CA2796161C/en not_active Expired - Fee Related
- 2010-11-10 DK DK10782482.3T patent/DK2501703T3/da active
- 2010-11-10 EA EA201290352A patent/EA020848B1/ru not_active IP Right Cessation
- 2010-11-10 PE PE2012000659A patent/PE20121430A1/es active IP Right Grant
- 2010-11-10 MX MX2012005691A patent/MX2012005691A/es active IP Right Grant
- 2010-11-10 MY MYPI2012002117A patent/MY160665A/en unknown
- 2010-11-10 EP EP10782482.3A patent/EP2501703B1/en active Active
- 2010-11-10 CN CN201080051850.4A patent/CN102612520B/zh not_active Expired - Fee Related
- 2010-11-10 WO PCT/US2010/056180 patent/WO2011060035A1/en not_active Ceased
- 2010-11-10 NZ NZ600006A patent/NZ600006A/en not_active IP Right Cessation
- 2010-11-10 RS RS20130485A patent/RS53018B/sr unknown
- 2010-11-10 ME MEP-2013-118A patent/ME01537B/me unknown
- 2010-11-10 ES ES10782482T patent/ES2435814T3/es active Active
- 2010-11-10 US US12/943,187 patent/US8232289B2/en not_active Expired - Fee Related
- 2010-11-10 JP JP2012538935A patent/JP5680101B2/ja not_active Expired - Fee Related
- 2010-11-10 PH PH1/2012/500969A patent/PH12012500969A1/en unknown
- 2010-11-10 SI SI201030388T patent/SI2501703T1/sl unknown
- 2010-11-10 HR HRP20130967AT patent/HRP20130967T1/hr unknown
-
2012
- 2012-04-23 ZA ZA2012/02967A patent/ZA201202967B/en unknown
- 2012-04-23 IL IL219370A patent/IL219370A/en not_active IP Right Cessation
- 2012-05-04 CO CO12073055A patent/CO6541545A2/es active IP Right Grant
- 2012-05-11 HN HN2012001011A patent/HN2012001011A/es unknown
- 2012-05-11 DO DO2012000135A patent/DOP2012000135A/es unknown
- 2012-05-14 MA MA34869A patent/MA33751B1/fr unknown
- 2012-05-16 EC ECSP12011902 patent/ECSP12011902A/es unknown
-
2013
- 2013-02-26 CR CR20130087A patent/CR20130087A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01537B (me) | Spojevi spiropiperidona kao antagonisti receptora orl-1 | |
| HRP20130969T1 (hr) | Spojevi spiropiperidona kao antagonisti receptora orl-1 | |
| RU2437888C2 (ru) | Ингибиторы фосфоинозитид-3-киназы и содержащие их фармацевтические композиции | |
| JP2013510859A5 (me) | ||
| US20180153888A1 (en) | Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virus | |
| JP2014531449A5 (me) | ||
| RU2015143430A (ru) | Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств | |
| HRP20191220T1 (hr) | Disupstituirani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora | |
| JP2019512482A5 (me) | ||
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2013507446A5 (me) | ||
| JP2016516026A5 (me) | ||
| HRP20170363T1 (hr) | Derivati piridina kao inhibitori kinaze pregrađene prilikom transfekcije (ret) | |
| JP2016538313A5 (me) | ||
| HRP20210447T1 (hr) | Piridinski spoj | |
| JP2015510938A5 (me) | ||
| JP2016519685A5 (me) | ||
| RU2014151009A (ru) | Пиразолопиримидоновые и пиразолопиридоновые ингибиторы танкиразы | |
| HRP20180528T1 (hr) | Derivati naftiridina, korisni kao antagonisti alfa-v-beta-6 integrina | |
| JP2012515787A5 (me) | ||
| SI2978752T1 (en) | 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD | |
| RU2015137103A (ru) | Фуропиридины в качестве ингибиторов бромодоменов | |
| HRP20241222T1 (hr) | Makrociklički spojevi kao agonisti sting, te postupci i njihova upotreba | |
| JP2004527560A5 (me) | ||
| RU2014152257A (ru) | Гетероциклильные пиримидиновые аналоги в качестве ингибиторов tyk2 |